Clinical Trial

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-11-11; most recent amendment 2025-09-04.
Status change: Recruiting → Active, Not Recruiting 2025-09-04
Status change: Active, Not Recruiting → Recruiting 2023-02-15
Status change: Recruiting → Active, Not Recruiting 2021-02-25
Status change: Not Yet Recruiting → Recruiting 2021-02-23
Trial Details
NCT Number NCT04632108
Lead Sponsor Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Collaborators: Jiangsu Aosaikang Biopharmaceutical Co., Ltd
Conditions Malignant Solid Tumor
Enrollment 199 participants
Start Date 2021-01-28
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-11